期刊文献+

MiR-451在甲状腺乳头状癌中的表达及其临床诊断价值 被引量:1

The expression of miR-451 in thyroid papillary carcinoma and its value of the clinical diagnosis
下载PDF
导出
摘要 目的:探讨miR-451在甲状腺乳头状癌中表达及其与临床诊断的关系。方法:收集2005年7月-2007年7月在上海交通大学医学院附属新华医院甲状腺外科收治的60例甲状腺乳头状癌患者的临床资料及对应的石蜡组织。用荧光定量PCR检测miR-451,比较其在甲状腺癌组织和癌旁组织中的表达差异。结果:MiR-451的表达水平甲状腺癌组织显著低于癌旁组织[(38.79±27.26)vs(12.62±13.44),P=0.000]。此外,miR-451表达水平与患者的性别、年龄、肿瘤大小、肿瘤位置均无显著相关性。但伴有淋巴结转移的甲状腺乳头状癌组织中miR-451表达水平显著低于不伴有淋巴结转移的甲状腺乳头状癌组织(P=0.006)。结论:MiR-451能区分甲状腺乳头状癌癌旁组织与癌组织,以及判断甲状腺乳头状癌患者是否伴有淋巴结转移,可能作为辅助的临床诊断指标。 Objective:To study the expression of miRNA-451 and its relationship with the clinical diagnosis in thyroid papillary carcinoma.Methods:From July 2005 to July 2007,we collected clinical data and pathological tissue of 60 patients with thyroid papillary carcinoma at Xinhua Hospital Affiliated the Shanghai Jiaotong University School of Medicine.Detecting miR-451 by using fluorescence quantitative PCR,comparing the differential expression between thyroid carcinoma and normal tissue.Results:Compared the adjacent tissues of cancer,the expression level of miR-451 in thyroid cancer tissues was significantly lower than that of normal tissues [(38.79 ±27.26) vs (12.62 ± 13.44),P =0.000].In addition,the expression level of miR-451 had no significant correlation with patients' age,gender,tumor size,but was significantly lower in which with lymph node metastasis than in which without lymph node metastasis (P =0.006).Conclusion:MiR-451 can distinguish cancer tissues from adjacent normal tissues,may be used as the auxiliary clinical diagnostic criteria with or without lymph node metastasis in papillary thyroid cancer.
出处 《现代肿瘤医学》 CAS 2015年第14期1971-1974,共4页 Journal of Modern Oncology
关键词 miR-451 甲状腺乳头状癌 淋巴结转移 临床诊断 miR-451 papillary thyroid carcinoma lymph node metastasis clinical diagnosis
  • 相关文献

参考文献3

二级参考文献44

  • 1Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 2001; 38:225-262.
  • 2Thomas CM, Sweep CG. Serum tumor markers: past, state of the art, and future, lnt J Biol Markers 2001; 16:73-86.
  • 3Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J lntern Med 2007; 18:175-184.
  • 4Roulston JE. Limitations of tumour markers in screening. Br J Surg 1990; 77:961-962.
  • 5Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-269.
  • 6Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-866.
  • 7Chen C, Ridzon DA, Broomer A J, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33:e179.
  • 8Tang F, Hajkova P, Barton SC, Lao K, Surani MA. MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res 2006; 34:e9.
  • 9Hafner M, Landgraf P, Ludwig J, et al. Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. Methods 2008; 44:3-12.
  • 10Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257-2261.

共引文献1027

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部